Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency

Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency  / Alberto M. Pereira, Agatha A. van der Klaauw, Hans P.F. Koppeschaar, Jan W.A. Smit, Sjoerd W. van Thiel, Jaap van Doorn, Nienke R. Biermasz, Ferdinand Roelfsema, Johannes A. Romijn. - (British Journal of Clinical Pharmacology 61 (2006) 4 (April); p. 451-455)

  • PMID: 16542206
  • PMCID: PMC1885043
  • DOI: 10.1111/j.1365-2125.2006.02585.x


Abstract

Aim: Needle-free administration of recombinant human growth hormone (rhGH) is effective in the treatment of growth hormone deficiency (GHD) in children, but has not been studied in adult patients. Therefore, we evaluated the efficacy of needle-free administration of rhGH in adults with GHD.

Methods: Insulin-like growth factor-I (IGF-I) concentrations were compared in newly diagnosed patients with GHD (n = 21) and in patients previously treated by subcutaneous injection of rhGH (switchers, n = 34), at baseline, 12 months and 24 months.

Results: In the new patients, IGF-I standard deviation scores (SDS) increased from - 1.82 +/- 0.46 to + 0.75 +/- 0.33 at 12 months and to + 0.65 +/- 0.41 at 24 months (P < or = 0.001 vs. baseline). In switchers, IGF-I SDS remained unchanged with values of + 0.98 +/- 0.32 at baseline, + 0.87 +/- 0.23 at 12 months and + 0.73 +/- 0.29 at 24 months (P = 0.696 vs. baseline). In new patients, the rhGH dose was 0.46 +/- 0.03 mg day(-1) at 12 months and 0.47 +/- 0.03 mg day(-1) at 24 months. In switchers, the rhGH dose was 0.53 +/- 0.04 mg day(-1) at baseline (s.c. injection), 0.52 +/- 0.03 mg day(-1) at 12 months and 0.48 +/- 0.03 mg day(-1) at 24 months (NS between the different time points). There was no difference in the dose of rhGH at 12 and 24 months between the two groups. Side-effects were generally minor and consisted of local tissue reactions.

Conclusion: Administration of rhGH by needle-free, transdermal injection is effective in maintaining IGF-I concentrations in the normal range for age in adults with GHD, and is as effective as traditional subcutaneous injection of rhGH.

Original document

Parameters

Science
Study
Date
2 February 2006
People
Biermasz, Nienke R.
Doorn, Jaap van
Klauw, Agatha A. van der
Koppeschaar, Hans P.F.
Pereira, Alberto M.
Roelfsema, Ferdinand
Romijn, Johannes A.
Smit, Johannes W.A.
Van Thiel, Sjoerd
Country
Netherlands
Language
English
Other organisations
Leids Universitair Medisch Centrum (LUMC) - Leiden University Medical Center
Doping classes
S2. Peptide Hormones, Growth Factors
Substances
Growth hormone (GH)
Medical terms
Legitimate Medical Treatment
Document category
Scientific article
Document type
Pdf file
Date generated
2 March 2021
Date of last modification
10 March 2021
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin